Evidence map›Paper›PMID 23604636›Full record

ArticleRNA (New York, N.Y.)2013

Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs.

Yi Shu, Farzin Haque, Dan Shu, Wei Li, Zhenqi Zhu, Malak Kotb, Yuri Lyubchenko, Peixuan Guo

Abstract read
In one paragraph

Article in RNA (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Molecular pharmaceutics · 2024
    Article
  10. Article
  11. Article
  12. Targeting oncogenicMolecular therapy. Nucleic acids · 2023
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yi ShuNanobiotechnology Center, Markey Cancer Center, and Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, USA.
Farzin Haque
Dan Shu
Wei Li
Zhenqi Zhu
Malak Kotb
Yuri Lyubchenko
Peixuan Guo

Funding

Nanotube and nanogold to gear phi29 DNA packaging motorR01EB003730 · NIBIB · UNIVERSITY OF KENTUCKY · PI GUO, PEIXUAN · 2004 to 2012
$2.3M
RNA Nanotechnology in Cancer TherapyU01CA151648 · NCI · UNIVERSITY OF KENTUCKY · PI GUO, PEIXUAN, LI, HENRY · 2010 to 2014
$2.1M
NCI NIH HHS CA151648NCI NIH HHS U01 CA151648NIBIB NIH HHS EB003730NIBIB NIH HHS R01 EB003730
6 · The paper itself

Abstract

Due to structural flexibility, RNase sensitivity, and serum instability, RNA nanoparticles with concrete shapes for in vivo application remain challenging to construct. Here we report the construction of 14 RNA nanoparticles with solid shapes for targeting cancers specifically. These RNA nanoparticles were resistant to RNase degradation, stable in serum for >36 h, and stable in vivo after systemic injection. By applying RNA nanotechnology and exemplifying with these 14 RNA nanoparticles, we have established the technology and developed "toolkits" utilizing a variety of principles to construct RNA architectures with diverse shapes and angles. The structure elements of phi29 motor pRNA were utilized for fabrication of dimers, twins, trimers, triplets, tetramers, quadruplets, pentamers, hexamers, heptamers, and other higher-order oligomers, as well as branched diverse architectures via hand-in-hand, foot-to-foot, and arm-on-arm interactions. These novel RNA nanostructures harbor resourceful functionalities for numerous applications in nanotechnology and medicine. It was found that all incorporated functional modules, such as siRNA, ribozymes, aptamers, and other functionalities, folded correctly and functioned independently within the nanoparticles. The incorporation of all functionalities was achieved prior, but not subsequent, to the assembly of the RNA nanoparticles, thus ensuring the production of homogeneous therapeutic nanoparticles. More importantly, upon systemic injection, these RNA nanoparticles targeted cancer exclusively in vivo without accumulation in normal organs and tissues. These findings open a new territory for cancer targeting and treatment. The versatility and diversity in structure and function derived from one biological RNA molecule implies immense potential concealed within the RNA nanotechnology field.

Indexed as

Drug Delivery SystemsAnimalsBase SequenceCell Line, TumorGene SilencingGenetic TherapyInverted Repeat SequencesMaleMiceMice, Inbred NODMice, NudeMice, SCIDNanoparticlesNanotechnologyNative Polyacrylamide Gel ElectrophoresisNeoplasms, ExperimentalRNAbacteriophage phi29nanobiotechnologyRNA nanoparticleRNA nanotechnologyRNA therapeuticstarget delivery

Identifiers

PMID23604636
PMCPMC3683911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.